(NASDAQ: MDCX) Medicus Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.85%.
Medicus Pharma's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast MDCX's revenue for 2028 to be $847,728,926, with the lowest MDCX revenue forecast at $847,728,926, and the highest MDCX revenue forecast at $847,728,926. On average, 1 Wall Street analysts forecast MDCX's revenue for 2029 to be $1,697,099,602, with the lowest MDCX revenue forecast at $1,697,099,602, and the highest MDCX revenue forecast at $1,697,099,602.
In 2030, MDCX is forecast to generate $3,397,599,969 in revenue, with the lowest revenue forecast at $3,397,599,969 and the highest revenue forecast at $3,397,599,969.